Transcenta
在场
Transcenta 是一家在股票代码 6628 (CN) 下上市的公司。
高管
查看带有其 18 名主要高管的组织结构图
Transcenta 搜索最多的简介
- Xueming Qian, Chief Executive Officer and Chairman of the Board
- Helen Chen, Independent Non-Executive Director
- Jiasong Tang, Independent Non-Executive Director
高管在Transcenta变化
- Li Xu已作为Non-Executive Director加入公司 (新闻发布的2024八月29号).
- Jonathan Zhao, Non-Executive Director, 已经离开公司 (新闻发布的2024六月10号).
创建提醒
跟踪 Transcenta 的高管变动
生物技术
Transcenta 拥有 2,316 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Biogen (美国(美洲))。
Popular M&A news in 生物技术
- AgomAb Therapeutics 刚刚宣布为 89 筹款数百万美元。 (公布2024十月29号).
- Seaport Therapeutics 刚刚宣布为 225 筹款数百万美元。 (公布2024十月25号).
- TuHura Biosciences and Kintara Therapeutics have merged (公布2024十月20号)..
生物技术 行业的其他推荐联系人
消息
Transcenta 的最新新闻稿
- Transcenta Updates Encouraging Efficacy Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ESMO 2024-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Debuts Encouraging Phase II Data from First-line Triple Combo Trial of Osemitamab (TST001) for G/GEJ Cancer at ASCO 2024-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Announces Collaboration with Agilent to Develop a Claudin 18.2 Companion Diagnostic to Support Osemitamab (TST001) Global Phase III Trial-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Presents Osemitamab (TST001) and TST003 Study Results at AACR 2024-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta to Present Two Clinical Trial Progress at ASCO 2023-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Completion of Enrollment in Cohorts C and G of China Phase II Clinical Study of Osemitamab (TST001) in Combination with CAPOX with or without Nivolumab as First-line Treatment of Gastric/Gastro-esophageal Junction Cancer Patients-TRANSCENTA HOLDING - A Gl
- Transcenta Presents Two Preclinical Studies at AACR 2023-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta’s Osemitamab (TST001) Targeting Claudin18.2 Granted Orphan Drug Designation for Treatment of Pancreatic Cancer-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta Announces First Patient Dosed in the U.S. Study of Its First-In-Class Gremlin1 Targeting Antibody TST003 for the Treatment of Solid Tumors-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- Transcenta to Present Two Preclinical Studies at AACR 2023-TRANSCENTA HOLDING - A Global Fully Integrated Biotherapeutics Company
- View more press releases Close
通过电子邮件
